{
    "Trade/Device Name(s)": [
        "LZI Oxycodone Enzyme Immunoassay",
        "LZI Oxycodone Drugs of Abuse (DAU) Calibrators",
        "LZI Oxycodone Drugs of Abuse (DAU) Controls"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K120763",
    "Predicate Device Reference 510(k) Number(s)": [
        "K050733"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "DLJ",
        "LAS"
    ],
    "Summary Letter Date": "April 27, 2012",
    "Summary Letter Received Date": "April 30, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3650",
        "21CFR862.3200",
        "21CFR862.3280"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxycodone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers",
        "Hitachi 717"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Homogeneous enzyme immunoassay",
        "Spectrophotometric measurement"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Oxycodone Enzyme Immunoassay, calibrators, and controls for qualitative and semi-quantitative detection of oxycodone in urine using automated analyzers.",
    "Indications for Use Summary": "Intended for qualitative and semi-quantitative determination of oxycodone in human urine at 100 and 300 ng/mL cutoffs with automated clinical chemistry analyzers; for professional use only; calibrators and controls are provided for calibration and quality control.",
    "fda_folder": "Toxicology"
}